Myeloid Malignancy Clinical Trial
Official title:
A Phase Ib Study of the Safety, Pharmacokinetic of APG-2575 Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML
The purpose of this study is to assess the safety, pharmacokinetic profile of APG-2575 single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
This is an open-label, multi-center Phase Ib study of safety, PK of APG-2575 as single agent or in combination with HHT or AZA in relapsed/refractory AML and related myeloid malignancies patients. This study consists of three stages: The first stage is the APG-2575 single agent dose-escalation study. The second stage is the APG-2575 combined with HHT/AZA dose-escalation study. The third stage is the MTD/RP2D expansion cohort study of the combination regimen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06090513 -
Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients
|
||
| Not yet recruiting |
NCT06129734 -
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05579769 -
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
|
Phase 2 | |
| Recruiting |
NCT05583175 -
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
|
Phase 2 | |
| Recruiting |
NCT06378437 -
A Study of GLB-001 in Patients With Myeloid Malignancies
|
Phase 1 | |
| Terminated |
NCT01596699 -
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04906031 -
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
|
Phase 2 | |
| Recruiting |
NCT05455294 -
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
|
Phase 1 | |
| Recruiting |
NCT03850418 -
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT02958462 -
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
|
N/A | |
| Recruiting |
NCT03855371 -
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
|
Phase 1 | |
| Recruiting |
NCT05841771 -
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
|
Phase 2 | |
| Recruiting |
NCT06434662 -
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
|
Phase 2 | |
| Completed |
NCT04214860 -
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT05350163 -
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
|
Phase 1 | |
| Not yet recruiting |
NCT05875805 -
A Telehealth Advance Care Planning Intervention
|
N/A |